SAN FRANCISCO — Stopping aspirin within 1 month of implanting a drug-eluting stent (DES) for acute coronary syndrome (ACS) followed by ticagrelor monotherapy was shown to be noninferior to 12 months ...

The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.

Please provide your email address to receive an email when new articles are posted on . Ticagrelor monotherapy after 3-month dual antiplatelet therapy reduced 1-year major bleeding vs. prolonged DAPT.

Please provide your email address to receive an email when new articles are posted on . For adults who undergo PCI with a drug-eluting stent, recommendations for dual antiplatelet therapy have evolved ...

When stopping dual antiplatelet therapy (DAPT) after PCI, it appears that a P2Y12 inhibitor is a better option than aspirin for continuing monotherapy, a network-meta-analysis suggests. The risk of MI ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting ...

While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an ...

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

SAN DIEGO, CA — Compared with stopping dual antiplatelet therapy (DAPT) at 12 months, extending therapy to 30 months reduced the risk of stent thrombosis and MI but also increased the risk of mild to ...

WASHINGTON -- Beyond bleeding alone, a regimen of dual antiplatelet therapy (DAPT) after transcatheter aortic valve replacement (TAVR) was associated with excess mortality, based on observational data ...

Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of ...